Theravance Biopharma, INC Form 4 insider transactions

Director Eran Broshy reports acquisition of shares and disposal of shares in Theravance Biopharma, Inc.

Director Alsup Laurie Smaldone reports acquisition and disposal of Theravance Biopharma shares and options.

Eli Samaha, managing partner of Madison Avenue Partners, LP, reports acquiring additional shares of Theravance Biopharma, Inc. through funds managed by the firm.

Theravance Biopharma's CEO, Rick Winningham, was granted 300,000 Restricted Stock Units (RSUs) on April 2, 2024, with vesting conditions based on service and share price appreciation.

Aziz Sawaf, SVP & CFO of Theravance Biopharma, received 100,000 restricted stock units (RSUs) on April 2, 2024, with vesting conditions based on service and share price appreciation.

Aine Miller, SVP at Theravance Biopharma, reports acquiring 37,500 ordinary shares on April 2, 2024.

Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc., was granted 100,000 Restricted Stock Units (RSUs) on April 2, 2024, with vesting conditions based on service and share price appreciation.

Rhonda Farnum, SVP at Theravance Biopharma, acquired 37,500 ordinary shares on April 2, 2024.

CEO Rick Winningham reports acquisition and gifting of Theravance Biopharma shares.